Phase 1 Stomach Cancer Trial, Recruiting NCT07298200 Sponsor: Jia Wei Condition: Stomach Cancer
Back to Stomach Cancer

Phase 1 Stomach Cancer Trial, Recruiting

NCT07298200
Recruiting Phase 1

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are willing and able to sign and date a consent form agreeing to take part.
  • You are between 18 and 70 years old (male or female).
  • You have been diagnosed with advanced stomach cancer confirmed by a lab test (biopsy or cell sample), and your cancer has not responded to or you could not tolerate standard second-line treatment, or standard treatment is not suitable for you at this stage.
  • You have at least one measurable area of cancer that can be tracked; the total size of all tumors (not counting any in bones) must be no larger than 100mm across, and no single tumor can be larger than 30mm across (confirm with trial site if you have had local treatments like radiotherapy).
  • Your doctors expect you to live for at least 12 weeks.
  • Your organs (such as liver and kidneys) and bone marrow are working well enough to take part.

Who may not be able to join:

  • You need long-term allergy medication taken throughout your body, or you have had a severe allergic reaction (grade 3 or higher) to the study drug or its ingredients.
  • You have cancer that has spread to your brain or the lining around your brain and it is causing symptoms and has not been treated.
  • You have taken immune-modifying medicines within 2 weeks before the first dose of the study drug.
  • You have a skin condition (such as psoriasis) that could stop the study drug from being injected properly under the skin.
  • You still have side effects from previous cancer treatments that have not improved to a mild level (grade 2 or lower), not counting hair loss.
  • You have taken steroid medicines at a dose above a certain level by mouth or through your body (rather than locally, such as a nasal spray or joint injection) within 7 days before the first study dose.
  • You have previously been treated with a cancer vaccine or a cell-based cancer therapy.
  • You have previously had a bone marrow or stem cell transplant from another person, or an organ transplant, or you are currently taking medicines to suppress your immune system.
  • You have a serious active or poorly controlled infection at the time of screening.
  • Your blood tests show you are positive for HIV, active Hepatitis B (with high virus levels), Hepatitis C, or syphilis.
  • You have had another type of cancer in the past 5 years, unless it was certain early-stage cancers (such as cervical, breast, or skin basal cell cancers) that were fully treated and cured.
  • You have any history of autoimmune disease (a condition where your immune system attacks your own body).
  • You have active tuberculosis (TB).
  • You have received chemotherapy, radiotherapy, targeted therapy, immunotherapy, hormone therapy, or any other trial treatment within 2 weeks before screening.
  • You are currently taking part in another clinical trial.
  • You are pregnant or breastfeeding.
  • You have other serious medical or mental health conditions, or abnormal lab results, that the study doctor believes could put you at risk or affect the study results.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 14 July 2026
Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: 0086-025-83304616

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 1
Sponsor
Jia Wei
Registry
ClinicalTrials.gov
Start date
26 December 2025
Est. completion
1 June 2028

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Adverse Event; Dose Limiting Toxicity

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 14 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov